{'fraction_non_alphanumeric': 0.018844221105527637, 'fraction_numerical': 0.0, 'mean_word_length': 5.532786885245901, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Genome‐wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas

PE and rituximab treatment, it seems more likely that recovery of renal function, TMA-associated thrombocytopenia, and haemolysis are a result of eculizumab treatment than a delayed response to PE and rituximab, presuming a dysregulation of the complement system in the pathology of gemcitabine-induced TMA. Our observation supports the hypothesis that there is probably no antibody-mediated cause in gemcitabine-induced TMA, so it is rather unlikely that PE, prednisolone and rituximab are efficacious in these cases. Bearing in mind that our observations are based on a single case, we conclude that larger prospective trials are warranted to investigate the definitive role of eculizumab in druginduced TMA.